June is seeing a wave of biotech IPOs. Five priced last week, and four more are on the IPO calendar for this week. Recent biotech IPOs have mostly underperformed, though 2 are up +100% Biotechs have driven 2019 healthcare IPOs with 25 of the 32...read more
Slack's (WORK) widely-covered direct listing was hailed as a success.
Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public investors ended the week ...read more
Stoke Therapeutics, a preclinical biotech developing RNA-targeted therapies for rare genetic diseases, raised $142 million by offering 7.9 million shares at $18, above the range of $14 to $16. The company had previously filed to offer 6.7 million shares. ...read more
A wave of biotechs are preparing to go public in June, with five on the IPO calendar for this week and four more scheduled for the week of June 24. Two others could soon launch June/July IPOs as well. ...read more
June's flood of biotech IPOs continues with these 4 deals
June is seeing a wave of biotech IPOs. Five priced last week, and four more are on the IPO calendar for this week. Recent biotech IPOs have mostly underperformed, though 2 are up +100% Biotechs have driven 2019 healthcare IPOs with 25 of the 32...read more
US IPO Weekly Recap: WORK's direct listing works as Slack and 6 others go public
Slack's (WORK) widely-covered direct listing was hailed as a success. Slack opened on Thursday at $38.50, well above the NYSE's "reference price" of $26, and more than triple its last round less than a year ago. And yet, new public investors ended the week ...read more
Genetic disease biotech Stoke Therapeutics prices upsized IPO above the range at $18
Stoke Therapeutics, a preclinical biotech developing RNA-targeted therapies for rare genetic diseases, raised $142 million by offering 7.9 million shares at $18, above the range of $14 to $16. The company had previously filed to offer 6.7 million shares. ...read more
June is getting a flood of biotech IPOs with these 9 deals on the calendar
A wave of biotechs are preparing to go public in June, with five on the IPO calendar for this week and four more scheduled for the week of June 24. Two others could soon launch June/July IPOs as well. ...read more